Stefaan De Koker, Ph.DNon-clinical Principle Scientist and site-Director at eTheRNA
Stefaan De Koker obtained his PhD at the lab for Molecular Immunology at Ghent University. During his academic career, he worked on unraveling how early activation of the innate immune system by adjuvants shapes adaptive immunity to vaccines. During the early days of the mRNA therapeutics field, Stefaan studied the role of type I interferons in shaping T cell responses to different mRNA vaccine modalities. September 2016, Stefaan joined eTheRNA where he works on developing novel strategies to improve the immunogenicity of in situ applied mRNA immunotherapies. Stefaan has authored over 60 publications and is co-inventor on multiple patent applications.